Arulanandam et al. demonstrate that HER2 positive cancer cells are sensitized to oncolytic rhabdovirus by an antibody-drug conjugate consisting of HER2- targeting trastuzumab linked to the microtubule destabiliser DM1. The gene discussed is ERBB2; the disease is cancer.